Lipocine Posts $2.6M Q2 Loss, Cash at $23.3M; FDA Meeting on PPD Drug Set for Q3
LPCN sits 17% above its 52-week low of $1.81.
Summary
Lipocine reported a $2.6 million net loss for Q2 2026, with $23.3 million in cash. The net loss widened as revenue declined, with research and development expenses at $2.0 million and a loss per share of 32 cents. The key update is an FDA meeting scheduled for Q3 to determine the regulatory path for its lead PPD drug, LPCN 1154, after a failed Phase 3 trial. The company has also started a new PPD trial and plans Phase 2 studies for MDD and essential tremor. This follows the Phase 3 failure in April and subsequent re-analysis presented in June. The FDA meeting is the next major catalyst for the stock.
At the time of this announcement, LPCN was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $1.81 to $12.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.